Cryo-Save Group N.V.

Revenue up 4% to EUR41.9 million

Cryo-Save Group N.V. (Euronext: CRYO, ´Cryo-Save´, or ´the Group´), the leading
international stem cell storage brand and the largest family stem cell bank in
Europe, has published its financial results for the year ended 31 December 2011.

Financial highlights

·         Revenue up 4% to EUR41.9 million (2010: EUR40.4 million)
·         Operating expenses before depreciation and amortisation increased with
EUR1.6 million mainly due to further investments in  Cryo-Lip(®) (EUR0.8 million)
and acquisition impact (EUR0.7 million)
·         EBITDA(*): EUR6.3 million (2010: EUR7.3 million)
·         EBITA(**): EUR4.5 million (2010: EUR5.8 million)
·         Operating profit: EUR2.9 million (2010: EUR4.5 million)
·         Profit before taxation: EUR3.0 million (2010: EUR3.9 million)
·         Net profit: EUR2.3 million (2010: EUR2.6 million)
·         Basic earnings per share 25.0 euro cents (2010: 27.6 euro cents)
·         Robust net cash from operating activities EUR6.2 million (2010: EUR 2.8
million)
·         Solid cash position of EUR7.0 million as at 31 December 2011 (2010: EUR6.0
million)
·         Dividend per share of EUR0.08, up 14% (2010: EUR0.07)
( )
(*) EBITDA is defined as Earnings Before Interest, Taxation Depreciation and
Amortisation
(**) EBITA is defined as Earnings Before Interest, Taxation and Amortisation of
identified intangible assets

Operational highlights

·         39,900 new samples stored in 2011, up 4% compared to previous year
(2010: 38,300). Of these, 25,200 were new cord blood samples and 14,700 new cord
tissue samples
·         204,000 samples have been stored in total at 31 December 2011
·         67% of new customers opt for combined service of cord blood and cord
tissue storage
·         Acquisition of Serbian distributor Life R.F. for EUR2.3 million in cash
and 30,000 Cryo-Save shares
·         Cryo-Save USA founded, to commercialize and develop the Cryo-Lip(®)
service in North America
·         Cryo-Save South Africa joint venture established and stem cell
processing and storage laboratory opened in Cape Town together with John Daniel
Holdings and Lazaron Biotechnologies
·         A six-year-old girl from Portugal with Cerebral Palsy was treated at
Duke University in the US with her own cord blood stem cells, which were stored
and released by Cryo-Save

Outlook

* Cryo-Save has a strong strategic position and product portfolio to further
enhance its business
* Cryo-Save will continue to collaborate with new partners and make